Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone

被引:23
作者
vanGinkel, RJ
Koops, HS
deVries, EGE
Molenaar, WM
Uges, DRA
Hoekstra, HJ
机构
[1] UNIV GRONINGEN HOSP,DEPT SURG ONCOL,GRONINGEN,NETHERLANDS
[2] UNIV GRONINGEN HOSP,DEPT MED ONCOL,GRONINGEN,NETHERLANDS
[3] UNIV GRONINGEN HOSP,DEPT PATHOL,GRONINGEN,NETHERLANDS
[4] UNIV GRONINGEN HOSP,DEPT PHARM,GRONINGEN,NETHERLANDS
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 1996年 / 22卷 / 05期
关键词
hyperthermia; perfusion; cisplatin; osteosarcoma; malignant fibrous histiocytoma; sarcoma;
D O I
10.1016/S0748-7983(96)93114-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The value of hyperthermic isolated limb perfusion (HILP),vith cisplatin in the management of locally advanced soft tissue sarcomas or metastatic bone sarcoma was studied, Four patients mere treated with HILP under mild hyperthermia (39-40 degrees C) with 20-30 mg cisplatin/l perfused limb volume, Toxicity in the perfused limbs was moderate, and the erythema and oedema that occurred resolved spontaneously within 7-14 days as did the slight motor and sensory neuropathy over a longer period of time. Clinically, a reduction of pain was observed in all patients, Two weeks after perfusion, tumour biopsies were taken to evaluate tumour response, Two patients showed a pathological complete response, one patient showed >90% necrosis and one patient showed no response. Currently patients are treated with tumour necrosis factor and melphalan as perfusion agents. The above-mentioned results make the combination of tumour necrosis factor with cisplatin in the isolated limb perfusion setting an interesting option.
引用
收藏
页码:528 / 531
页数:4
相关论文
共 30 条
[1]
AIGNER K, 1983, LANGENBECK ARCH CHIR, V359, P113
[2]
CASPER ES, 1994, CANCER, V73, P1644, DOI 10.1002/1097-0142(19940315)73:6<1644::AID-CNCR2820730616>3.0.CO
[3]
2-V
[4]
COOMBS R, 1987, BONE TUMOUR MANAGEME, P81
[5]
CHEMOTHERAPY OF CANCER - REGIONAL PERFUSION UTILIZING AN EXTRACORPOREAL CIRCUIT [J].
CREECH, O ;
KREMENTZ, ET ;
RYAN, RF ;
WINBLAD, JN .
ANNALS OF SURGERY, 1958, 148 (04) :616-632
[6]
DEVRIES J, 1987, SURG RES COMMUN, V2, P107
[7]
EGGERMONT AMM, 1992, P AM SOC CLIN ONCOL, V11, P1444
[8]
ADJUVANT CHEMOTHERAPY FOR OSTEOSARCOMA - A RANDOMIZED PROSPECTIVE TRIAL [J].
EILBER, F ;
GIULIANO, A ;
ECKARDT, J ;
PATTERSON, K ;
MOSELEY, S ;
GOODNIGHT, J .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :21-26
[9]
PHARMACOKINETICS AND RESULTS OF DOSE-ESCALATION IN CISPLATIN HYPERTHERMIC ISOLATION LIMB PERFUSION [J].
FLETCHER, WS ;
POMMIER, RF ;
WOLTERING, EA ;
MUELLER, CR ;
ASH, KO ;
SMALL, KA .
ANNALS OF SURGICAL ONCOLOGY, 1994, 1 (03) :236-243
[10]
FONTIJNE WPJ, 1985, CANCER, V55, P1455, DOI 10.1002/1097-0142(19850401)55:7<1455::AID-CNCR2820550706>3.0.CO